CD8A and melanoma: In this post‐hoc analysis, we report long‐term clinical outcomes of a randomized phase II clinical trial (Mel39, NCT00938223) that tested the immunogenicity of two multipeptide vaccines designed to stimulate CD8+ T cells in patients with high‐risk melanoma.